Australia's most trusted
source of pharma news
Thursday, 06 August 2026
Posted 6 August 2026 AM
BMS has submitted Breyanzi to MSAC, the first sign that the company is working to provide the CAR-T cell therapy to Australians with large B-cell lymphoma (LBCL).
The application set to be considered by MSAC’s subcommittee ESC in October before consideration at the November 2026 MSAC meeting, seeks funding for Breyanzi under the National Health Reform Agreement Addendum (highly specialised therapies (HSTs)) for patients with confirmed relapsed/refractory LBCL.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.